Shares of Capricor Therapeutics climbed 7.6% to $30.01 in early trading on Monday, March 9, 2026, following the company's announcement that it will report its fourth-quarter and full-year financial results on March 12. The upcoming update has refocused investor attention on deramiocel, the firm's investigational cell therapy for Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration.
The company plans to publish its financial figures after the market closes on Thursday, March 12, and will host a conference call at 4:30 p.m. Eastern Time. This event is strategically timed, as Capricor continues efforts to revive the U.S. regulatory pathway for deramiocel in DMD-associated cardiomyopathy. The therapy previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in July, which cited insufficient evidence of effectiveness and issues with a portion of the manufacturing submission.
Critical Phase 3 Data Presentation
Adding to the significance of the week, Capricor is scheduled to present comprehensive results from its pivotal HOPE-3 trial at the Muscular Dystrophy Association (MDA) conference on March 11 in Orlando. The presentation is slated for 2:45 p.m. ET. According to a conference abstract released earlier, the 106-patient Phase 3 study met both its primary skeletal-muscle and cardiac endpoints.
The data showed deramiocel achieved a placebo-adjusted improvement of 4.55% on the Performance of Upper Limb (PUL) test, which measures arm and hand function. For cardiac efficacy, the therapy demonstrated a 2.4 percentage-point increase in left ventricular ejection fraction, a key indicator of heart pumping capacity. The abstract also noted no imbalance in severe or serious adverse events between the treatment and placebo groups.
In a December statement, Dr. Craig McDonald, the national principal investigator for the trial at UC Davis, characterized the approximate 54% reduction in skeletal-muscle decline as "extraordinary in Duchenne." Separately, pediatric cardiologist Dr. Jonathan Soslow of Vanderbilt University stated the cardiac outcomes represent a "significant advance" for a disease where heart failure is the leading cause of mortality.
Regulatory Path and Analyst Sentiment
Following the FDA's rejection last summer, the agency subsequently requested the complete HOPE-3 study report and supporting data as part of the ongoing review of the company's Biologics License Application (BLA). Notably, the FDA did not ask for an additional clinical trial or new patient information. CEO Linda Marbán described this request in January as "expected and appropriate." In February, she highlighted that the late-breaking presentation slot at the MDA meeting underscored the "strength" of the clinical evidence and reaffirmed the company's focus on securing a potential approval.
Wall Street analysis has turned more optimistic following the release of topline data in December. B. Riley Securities analyst Madison El-Saadi noted the HOPE-3 trial's efficacy signal was "unambiguous" across all endpoints and expressed anticipation for eventual regulatory approval.
Financial Position and Market Context
Beyond the clinical pipeline, Capricor's financial health will be under scrutiny. As of September 30, the company held approximately $98.6 million in cash, cash equivalents, and marketable securities. Management has stated this reserve is sufficient to fund operations into the fourth quarter of 2026. The firm reported zero revenue for the third quarter, having exhausted prior milestone payments from its partner Nippon Shinyaku.
Capricor's cell-therapy approach enters a DMD treatment landscape where safety remains a paramount concern. Sarepta Therapeutics' gene therapy Elevidys is the only such treatment approved in the U.S., but the FDA mandated a boxed warning—its most serious safety alert—in November following reports of fatal liver injury in non-ambulatory patients.
Despite the encouraging data, Capricor faces unresolved challenges. Its pipeline contains no currently marketed therapies, the FDA has not provided a new decision timeline, and it remains uncertain whether the HOPE-3 data and manufacturing revisions will fully address the agency's previous concerns. Investors will be closely monitoring the MDA presentation on March 11 and the subsequent earnings call for clarity on these pivotal issues.